European Business Expenditure on R&D in Basic Pharmaceutical Products and Pharmaceutical Preparations Manufacturing by Country

Switzerland leads European Business R&D expenditure in the pharmaceutical sector with €852.37 per capita, showcasing strong investment. Belgium follows with €446.69, reflecting significant growth with a 9.77% increase in 2023. Other notable countries include Sweden (€119.09) and Hungary (€55.92), though growth is more moderate. Smaller economies like Malta and Slovakia saw varied changes, with Malta increasing by 6.1% and Slovakia decreasing by 8.67%. Over the past five years, trends indicate consistent investment growth across Europe, with Switzerland and Belgium leading.

Looking ahead, expect further investment growth, particularly in innovation-focused economies like Switzerland and Belgium. Potential changes in regulatory environments and focus on biopharmaceuticals may influence future R&D strategies and expenditure across Europe.